Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16538914 | 0.88 | CYP11B2 (0.49) | ROCK1CXCR4CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL3131128 | 0.82 | PLA2G4A (0.51) | ROCK1CXCR4SLC6A2CYP2A6KDM4C | |
| SCHEMBL8306084 | 0.81 | CYP19A1 (0.53) | CYP11B2CYP11B1CYP3A4CYP2A6CYP2E1 | |
| SCHEMBL30364924 | 0.81 | MAPT (0.48) | CYP11B2CYP3A4CYP2A6CYP2E1KDM4C | |
| SCHEMBL17067754 | 0.81 | ROCK1 (0.50) | ROCK1CYP11B2CYP11B1CYP3A4CYP2A6 | |
| SCHEMBL2264468 | 0.81 | MAPT (0.48) | CYP11B2CYP3A4CYP2A6CYP2E1KDM4C | |
| SCHEMBL6657897 | 0.81 | CYP11B2 (0.55) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL6846125 | 0.80 | CYP11B2 (0.59) | CYP11B2CYP11B1CYP3A4CYP2A6CYP1A2 | |
| Hydrochloric Acid SCHEMBL6656724 | 0.80 | MAPT (0.47) | CYP11B2CYP3A4CYP2A6CYP2E1KDM4C | |
| Hydrochloric Acid SCHEMBL6654905 | 0.80 | MAPT (0.47) | CYP11B2CYP3A4CYP2A6CYP2E1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946205-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2430031-B1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120184527-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| CN-102439015-A | 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-4536505-A | THROMBOXANE SYNTHETASE INHIBITOR, ANTIISCHEMIC, ANTIARRHYTHMIA, ANTIINFLAMMATORY AND HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0126401-A1 | Indole compounds | CIBA-GEIGY AG (CH) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | ROCK1 1126/4885CXCR4 3724/4885CYP11B2 53/4885 |
| US-20120184527-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | ROCK1 2500/4885CXCR4 1412/4885CYP11B2 979/4885 |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | ROCK1 353/4885CXCR4 791/4885CYP11B2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.